Asthma Management with Long-Acting Inhalers

Introduction to Asthma Treatment

The American College of Allergy, Asthma, and Immunology recommends ICS/LABA combination inhalers as the first-choice long-acting inhaler for patients with moderate to severe persistent asthma requiring step 3 care or higher, with fluticasone/salmeterol and budesonide/formoterol being the preferred evidence-based options 1, 2

The American Thoracic Society states that LABAs must never be used as monotherapy for asthma due to increased risk of asthma-related deaths, hospitalizations, and intubations, and should only be prescribed in fixed-dose combination with inhaled corticosteroids 1, 3

The National Asthma Education and Prevention Program recommends ICS/LABA combination therapy as the preferred adjunctive treatment when low-to-medium dose ICS alone does not adequately control asthma (step 3 care), with fluticasone/salmeterol and budesonide/formoterol being the two main evidence-based combinations 1, 2, 3
Adding a LABA to ICS is more effective than doubling the ICS dose alone for achieving asthma control, according to the American College of Chest Physicians 2, 3

The American Academy of Allergy, Asthma, and Immunology recommends a stepwise approach to asthma treatment, starting with as-needed SABA only for intermittent asthma, and progressing to low-dose ICS daily + as-needed SABA for mild persistent asthma, and then to low-to-medium dose ICS + LABA (preferred) or medium-to-high dose ICS alone for moderate persistent asthma 1, 2, 4

The European Respiratory Society states that leukotriene receptor antagonists (LTRAs) are alternative, but not preferred, adjunctive therapy compared to LABAs, as ICS/LABA combinations provide greater improvements in lung function and asthma control compared to ICS/LTRA combinations 1, 2

The American College of Allergy, Asthma, and Immunology recommends monitoring SABA use, as increasing use (>2 days/week for symptom relief) indicates inadequate asthma control and necessitates stepping up therapy 1, 4, 5
Patients must understand that their LABA-containing inhaler is for maintenance therapy, not acute symptom relief, and should use their SABA for acute symptoms, according to the National Asthma Education and Prevention Program 3, 6, 5